Press Release




Sensorion Announces an Increase in Resources Allocated
to the Liquidity Contract with Kepler Cheuvreux

Montpellier, August 15, 2025, 7.30 am CET – Sensorion (FR0012596468 – ALSEN) a pioneering
clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat
and prevent hearing loss disorders, today announces an increase in resources allocated to the liquidity
contract entrusted to Kepler Cheuvreux.

On 15 December 2017 Sensorion entered into a Liquidity Contract with Kepler Cheuvreux, modified by
amendments dated 7 December 2018 and 15 July 2022 (the "Contract"). This Contract aims to promote
the liquidity of the Shares of Sensorion on Euronext Paris.

On 14 August 2025, in accordance with Article 4 of AMF Decision No. 2021-01 of 22 June 2021 renewing
the establishment of liquidity contracts on equity securities as an accepted market practice, Sensorion
increased the resources allocated to the liquidity contract by €60,000.

Following this increase in resources, as of 14 August 2025, the following assets appear on the liquidity
account:

- 206,211 Sensorion Ordinary Shares
- €66,965.21


About Sensorion
Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies
to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a
unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear
related diseases, enabling it to select the best targets and mechanisms of action for drug candidates.
It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the
framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-
501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the
gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially
address important hearing loss segments in adults and children. The Company is also working on the identification
of biomarkers to improve diagnosis of these underserved illnesses.
Sensorion’s portfolio also comprises programs of a clinical-stage small molecule, SENS-401 (Arazasetron), for the
treatment and prevention of hearing loss disorders. Sensorion’s small molecule progresses in a Phase 2 proof of
concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) for the preservation of residual hearing.
Sensorion, with partner Cochlear Limited, completed in 2024 a Phase 2a study of SENS-401 for the residual hearing
preservation in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in
Sudden Sensorineural Hearing Loss (SSNHL) in January 2022.
www.sensorion.com
Press Release

Contacts

Investor Relations Press Relations
Noémie Djokovic, Investor Relations and Ulysse Communication
Communication Associate Bruno Arabian / 00 33(0)6 87 88 47 26
ir.contact@sensorion-pharma.com barabian@ulysse-communication.com
Nicolas Entz / 00 33 (0)6 33 67 31 54
nentz@ulysse-communication.com


Label: SENSORION
ISIN: FR0012596468
Mnemonic: ALSEN




Disclaimer
This press release contains certain forward-looking statements concerning Sensorion and its business. Such
forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there
can be no assurance that such forward-looking statements will be verified, which statements are subject to
numerous risks, including the risks set forth in the 2024 full year report published on March 14, 2025, and available
on our website and to the development of economic conditions, financial markets and the markets in which
Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not
yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such
risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially
different from such forward-looking statements. This press release and the information that it contains do not
constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares
in any country. The communication of this press release in certain countries may constitute a violation of local laws
and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply
therewith.